Europe Emphysema Treatment Market Size, Share & Industry Trends Analysis Report By Medication Type, By Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers), By Country and Growth Forecast, 2022 - 2028

Europe Emphysema Treatment Market Size, Share & Industry Trends Analysis Report By Medication Type, By Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers), By Country and Growth Forecast, 2022 - 2028

The Europe Emphysema Treatment Market would witness market growth of 6.6% CAGR during the forecast period (2022-2028).

Emphysema is a major subclass of chronic obstructive pulmonary disease (COPD) if it is associated with significant airflow limitation. COPD is a progressive lung disease characterized by long-term breathing complications and poor airflow. Even in the absence of COPD, emphysema on a CT lung scan is associated with a significantly increased risk of death among cigarette users. The first signs of emphysema might manifest differently in each individual with the disease. A cough (with or without sputum), wheezing, a rapid breathing rate, shortness of breath on exercise, and a sense of tightness in the chest may be present. There is a possibility of frequent infections with the cold or flu.

Damage to the air sacs, which may be caused by emphysema, can result in a change in the form of the air sacs or, more often, their destruction. This causes a decrease in the amount of gas that is exchanged in the lungs, which leads to trouble breathing. In addition, the damage done to the thin membrane that lines the air sacs cannot be repaired, resulting in a decreased amount of oxygen traveling through the bloodstream.

In England, smoking is expected to be the top avoidable cause of sickness and premature death in 2019, taking the lives of around 74,600 individuals. It is anticipated that there were 506,100 smoking-related hospital admissions in England in the year 2019 to 2020; this is equivalent to about 1,400 entries on a daily basis. Smokers make up one in every four people occupying a bed in a hospital. In addition, smokers go to the doctor 35% more often than non-smokers.

It is anticipated that the number of people living with chronic obstructive pulmonary disease (COPD) in France would rise to 2.8 million by 2025, from the current prevalence estimate of 2.6 million. In addition, there is a dearth of evidence on treating COPD within the context of private healthcare settings. These factors provide potential expansion prospects for investors operating in the regional emphysema market.

The Germany market dominated the Europe Emphysema Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $361.6 million by 2028. The UK market is anticipated to grow at a CAGR of 5.7% during (2022 - 2028). Additionally, The France market would experience a CAGR of 7.4% during (2022 - 2028).

Based on Medication Type, the market is segmented into Bronchodilators, Steroids, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc

Scope of the Study

Market Segments covered in the Report:

By Medication Type

  • Bronchodilators
  • Steroids
  • Others
By Distribution Channel
  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Viatris, Inc.
  • Orion Corporation
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Hikma Pharmaceuticals PLC
  • Boehringer Ingelheim International GmbH
  • Verona Pharma Plc
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Emphysema Treatment Market, by Medication Type
1.4.2 Europe Emphysema Treatment Market, by Distribution Channel
1.4.3 Europe Emphysema Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Emphysema Treatment Market
Chapter 4. Europe Emphysema Treatment Market by Medication Type
4.1 Europe Bronchodilators Market by Country
4.2 Europe Steroids Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Emphysema Treatment Market by Distribution Channel
5.1 Europe Drug Stores & Retail Pharmacies Market by Country
5.2 Europe Hospital Pharmacies Market by Country
5.3 Europe Online Providers Market by Country
Chapter 6. Europe Emphysema Treatment Market by Country
6.1 Germany Emphysema Treatment Market
6.1.1 Germany Emphysema Treatment Market by Medication Type
6.1.2 Germany Emphysema Treatment Market by Distribution Channel
6.2 UK Emphysema Treatment Market
6.2.1 UK Emphysema Treatment Market by Medication Type
6.2.2 UK Emphysema Treatment Market by Distribution Channel
6.3 France Emphysema Treatment Market
6.3.1 France Emphysema Treatment Market by Medication Type
6.3.2 France Emphysema Treatment Market by Distribution Channel
6.4 Russia Emphysema Treatment Market
6.4.1 Russia Emphysema Treatment Market by Medication Type
6.4.2 Russia Emphysema Treatment Market by Distribution Channel
6.5 Spain Emphysema Treatment Market
6.5.1 Spain Emphysema Treatment Market by Medication Type
6.5.2 Spain Emphysema Treatment Market by Distribution Channel
6.6 Italy Emphysema Treatment Market
6.6.1 Italy Emphysema Treatment Market by Medication Type
6.6.2 Italy Emphysema Treatment Market by Distribution Channel
6.7 Rest of Europe Emphysema Treatment Market
6.7.1 Rest of Europe Emphysema Treatment Market by Medication Type
6.7.2 Rest of Europe Emphysema Treatment Market by Distribution Channel
Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals and Trials:
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Viatris, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.5 Orion Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 GlaxoSmithKline PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Product Launches and Product Expansions:
7.6.5.2 Approvals and Trials:
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Hikma Pharmaceuticals PLC
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.10. Verona Pharma Plc
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expenses

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings